Neue Konzepte der Therapie venöser Thromboembolien...Neue Konzepte der Therapie venöser...
Transcript of Neue Konzepte der Therapie venöser Thromboembolien...Neue Konzepte der Therapie venöser...
Neue Konzepte der Therapie venöser Thromboembolien
Paul Kyrle
Univ. Klinik f. Innere Medizin I AKH/Medizinische Universität Wien
Therapie der VTE – verschiedene Möglichkeiten
Thrombolyse - hämodynamisch instabile PE, 4-Etagen tVT (?)
UFH - Niereninsuffizienz, hohes Blutungsrisiko
- Cave: HIT II (~ 2 %)
Fondaparinux NMH
Therapie der VTE mit NMH/VKA
gewichtsadaptiert („therapeutische Dosis“) 1 x oder 2 x tgl. s.c. mindestens 5 Tage bis INR mindestens 24 Stunden > 2
VKA ab Tag 1, mindestens 3 Monate (INR 2-3)
Treatment of VTE: past, present and future
Heparin Vitamin K antagonists
Heparin Dabigatran/Edoxaban
Rivaroxaban/Apixaban
Treatment of VTE: past, present and future
Heparin Vitamin K antagonists
Heparin Dabigatran/Edoxaban
Rivaroxaban/Apixaban
Treatment of VTE
acute subacute extended
up to 2 weeks up to 3 - 6 months > 6 months
Idraparinux vs. Heparin/VKA – van Gogh-PE
The van Gogh Investigators. N Engl J Med 2007;357:1094-1104
E R
Initial parenteral therapy
Single-dummy period
Double-dummy period
6 months End of treatment
Until INR ≥ 2.0
Warfarin Warfarin (INR 2.0–3.0)
Dabigatran placebo
Warfarin placebo
Dabigatran Warfarin placebo
E= enrolment R= randomization
LMWH/Dabigatran vs. LMWH/VKA for acute VTE
Schulman, N Engl J Med 2009
RE-COVER
Schulman, N Engl J Med 2009
Recurrent VTE and related death
RE-COVER - Dabigatran for acute/subacute VTE
Non-inferiority p<0.001
RE-COVER - Dabigatran for acute/subacute VTE
Schulman, N Engl J Med 2009
Bleeding
EINSTEIN: Rivaroxaban for acute VTE
15 mg bid
Objectively confirmed DVT
without symptomatic
PE N=~2,900 Rivaroxaban
Day 1 Day 21
Enoxaparin 1.0 mg/kg bid for at least 5 days, followed by
VKA to start ≤48 hours, target INR 2.5 (INR range 2–3)
Objectively confirmed PE
with or without symptomatic
DVT
EINSTEIN DVT/PE Treatment period of 3, 6 or 12 months
20 mg od
N=~3,300
30-d
ay o
bser
vatio
n
pe
riod
Rivaroxaban
R
Randomized, open-label, event-driven, non-inferiority study
EINSTEIN-DVT - Rivaroxaban for acute DVT
EINSTEIN Investigators, N Engl J Med 2010
Recurrent VTE and related death
HR=0.68 (95% CI: 0.44–1.04)
p<0.001 for non-inferiority
p=0.08 for superiority
Clinically significant bleeding
EINSTEIN-DVT - Rivaroxaban for acute DVT
EINSTEIN Investigators, N Engl J Med 2010
EINSTEIN-PE
Büller et a., NEJM 2012
EINSTEIN-PE
Büller et a., NEJM 2012
EINSTEIN-PE
Büller et a., NEJM 2012
Treatment of VTE
acute subacute extended
up to 2 weeks up to 3 - 6 months > 6 months
NOACS as safe and effective
NOACS as effective, but safer
Transient risk factors
Annualized event rate/pt-year (95% CI)
Any transient RF 3.3% (2.8 – 3.9)
Surgery 0.7% (0 – 1.5)
Nonsurgical RF 4.2% (2.8 – 5.6)
Iorio, Arch Intern Med 2012 (systematic review of 15 studies)
Risk of recurrence after unprovoked VTE
Kyrle, Rosendaal & Eichinger, Lancet 2010
Years after Discontinuation of Anticoagulation
Cum
ulat
ive
Pro
babi
lity
of R
ecur
renc
e (%
) p < 0,001 distal DVT
proximal DVT
symptomatic PE +/- DVT
RR (95% CI): distal 1 proximal 2,5 (1,6 – 3,9) PE 2,4 (1,5 – 3,7)
n = 151
n = 347
n = 333
Rezidivrisiko der VTE
Antikoagulation - VKA - NOAK
Aspirin Therapie nach Risikostratifitierung
Confirmed symptomatic DVT or PE completing 6 or 12 months of
rivaroxaban or VKA in EINSTEIN VTE
program
Rivaroxaban 20 mg od
Placebo Day 1
R
N=1,197
Treatment period of 6 or 12 months
30-d
ay o
bser
vatio
nal p
erio
d
Confirmed symptomatic DVT or PE completing 6 or 12 months
of VKA
~53%
~47%
Randomized, double-blind, placebo-controlled, event-driven (n=30), superiority study
EINSTEINext - Rivaroxaban for extended thromboprophylaxis after VTE
Study design
EINSTEIN Investigators, NEJM 2011
Continued treatment
EINSTEIN-DVT - Rivaroxaban for acute DVT
EINSTEIN Investigators, N Engl J Med 2010
Continued treatment
EINSTEIN-DVT - Rivaroxaban for acute DVT
EINSTEIN Investigators, N Engl J Med 2010
4 major bleeds
no major bleeds
AMPLIFY - Extended
Agnelli, NEJM 2012
AMPLIFY - Extended
Agnelli, NEJM 2012
RE-MEDY™ study design
S, screening; R, randomization.
*Original protocol, 3–6 months of pre-treatment, then 18 months on study drug; amendment allowed 3–12 months of pre-treatment, then up to 36 months on study drug.
Confirmed VTE
Anticoagulant therapy
3–12 months*
S R
0–7 days until
INR ≤2.3
Screening/ baseline
Dabigatran etexilate 150 mg bid Warfarin placebo
Warfarin (INR 2.0–3.0) Dabigatran placebo
Up to 36 months* End of treatment
Follow up 30 days Treatment period
and “increased risk of
recurrence”
Time to first VTE or VTE-related death
Risk of first onset of any bleeding
0
0,5
1
1,5
2
2,5
3
Dabigatran 150 mg bid Warfarin13/1430
Major bleeding
0.9%
1.8%
HR 0.52 (95% CI: 0.27–1.02)
25/1426
Perc
enta
ge
p = 0.058
On treatment
48% RRR
RRR, relative risk reduction.
RESONATE
RESONATE
Rezidivrisiko der VTE
Antikoagulation - VKA - NOAK
Aspirin Therapie nach Risikostratifitierung
WARFASA
WARFASA
ASPIRE
ASPIRE
ASPIRE
WARFASA + ASPIRE
Rezidivrisiko der VTE
Antikoagulation - VKA - NOAK
Aspirin Therapie nach Risikostratifitierung
Prediction rules for recurrent VTE
• Men continue and HER DOO2 • Vienna Prediction Model
• DASH Score
• Ottawa Score (cancer patients only)
Preselection of risk factors
• 929 patients with first unprovoked VTE
• impact on the recurrence risk independently confirmed • simple assessment, reproducibility • clinical variables: age at venous thrombosis, sex,
location, BMI • laboratory variables: FV Leiden, prothrombin mutation,
D-Dimer
Eichinger, Circulation 2010
Vienna Prediction Model
RFs after forward selection
• sex • location (distal vs. proximal vs. PE) • D-Dimer 3 weeks after cessation of anticoagulation
Eichinger, Circulation 2010
Vienna Prediction Model
http:/www.meduniwien.ac.at/user/georg.heinze/zipfile/ Circulation 2010;121:1630-1636 data supplement (free access)
Risk calculator
Vienna Prediction Model
Nomogram to predict recurrence: Vienna Prediction Model
Externe Validierung des VPM
Marcucci et al., ISTH 2013 Multizenterstudie Österreich (first patient in: Jänner
2013)